Artemisia Annua (Sweet Wormwood) trials recruiting now
2 registrations that name artemisia Annua as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 2 registrations
Status
Phase
1US sites across 1 state
1
2 to 4
5 to 19
20 or more
All 2 registrations
RecruitingNCT06721884
Herbal Evaluation Of Artemisia Annua For Small Intestinal Bacterial Overgrowth
Phase 1 and 2
National University of Natural Medicine
About 32 people
Started Jan 1, 2025
In plain words A Phase 1 and 2 study of artemisia Annua in people 18 and older, run by National University of Natural Medicine. It plans to enroll about 32 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Small Intestinal Bacterial Overgrowth Syndrome (SIBO).
Adults 18 years of age or older
IBS-SSS score >175
Meets North American Consensus criteria for H2 SIBO
Willing to take Artecinua™ or placebo as a dietary supplement for 5 weeks
5 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Artemisia Annua Leaf; placebo
Registered summary
Small intestinal bacterial overgrowth (SIBO) can cause symptoms like bloating, stomach pain, and changes in bowel movements, significantly affecting quality of life. Many people with irritable bowel syndrome (IBS) also have SIBO, and there is growing recognition of how important it is to address this condition. Artemisia annua has shown potential in managing SIBO based on early reports and studies suggesting it can fight bacteria like \*E. coli\* and \*Klebsiella\*, which are linked to a type of SIBO that produces hydrogen gas. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
Not yet recruitingNCT07819825
Artemisia Annua Infusion for the Treatment of Asymptomatic Plasmodium Falciparum Infection
Phase 1
Centre de Recherche Médicale de Lambaréné
About 20 people
Starts Sep 1, 2026 (estimated)
In plain words A Phase 1 study of artemisia Annua in people 18 to 45, run by Centre de Recherche Médicale de Lambaréné. It plans to enroll about 20 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 45. Conditions: Asymptomatic P.Falciparum Malaria.
Age: 18 to 45 years
Absence of fever (body temperature <37.5ºC axillary or <38.0°C oral, rectal or tympanic temperature)
Asymptomatic P. falciparum infection with parasitemia between 500 and 2,000 asexual P. falciparum parasites per μl of blood
Have been living in an endemic area for at least 5 years.
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Artemisia Annua Leaf; Centaurii herba
Registered summary
The goal of this clinical trial is to determine whether Artemisia annua dried leaves, used as an infusion, can treat individuals with malaria parasites but no symptoms. The main question it aims to answer is: Can Artemisia annua infusion be used to treat malaria? Researchers will compare those receiving Artemisia annua infusion with those receiving an infusion of Centaurii herba (which has no effect on malaria parasites) to see whether all individuals treated with Artemisia annua infusion are cured, which should not be the case for those receiving Centaurii herba infusion. The full summary is on the listing.